Abstract:

Aim: The microtubule inhibitor eribulin mesylate anthracycline and taxane resistance have been accepted for use in patients with metastatic breast cancer. The goal is to investigate the effectiveness of eribulin mesylate. Material and Methods: Retrospective study was carried out in New York City Medical Oncology clinic patients who were treated for metastatic breast cancer and who had received at least 2 serial chemotherapy including anthracycline and taxan. Results: A total of 25 patients were included in the study. Median age was 54.9 (range 36-73). Median follow-up time is 11.6 months. 68% of the patients were ER positive, 68% were Pr positive, 8.3% were HER2 positive and 6.2% were triple negative. 78% of the patients had liver, 64% had bone, and 36% had lung metastases. The treatment line number was 4.4 (min3-max6). The number of cycles of Eribulin was 6.6 (min 1-max 33). Median PFS is 6.6 (0-26) months and median OS is 17 (0-30). There were 8% complete response (2 patients), 12% (3 patients) partial response, 52% (13 patients) stable response and 28% (7 patients) progressive disease. There was no difference in survival according to patients' hormone receptor status and HER2 status (P = 0.187). There was no difference in survival according to the metastatic sites in the patients (P = 0.875). Grade 3 to 4 hematologic toxicity in 12% (3 patients) and grade 3-4 neuropathy in 4% (1 patient) in the patient,40% (10 patients) grade 1-2 hematologic toxicity in the patient, grade 1-2 neuropathy were seen Conclusion: Eribulin mesylate have been found to be effective and tolerable in line 3 and more than subsequent line in the treatment of patients with metastatic breast cancer who anthracycline and taxan resistance and previously received multiple line chemotherapy.

Keywords: